CVRx to present at William Blair Growth Stock Conference on June 2, 2026
CVRx, a medical device company, announced it will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026, in Chicago. The company will showcase its Barostim therapy, an FDA-approved device for heart failure. This presentation will offer insights into CVRx's commercial advancements and future prospects, with a live webcast available for investors.
CVRx to Present at the William Blair 46th Annual Growth Stock Conference
CVRx, Inc., a medical device company, announced that its management team will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026, at 10:40 a.m. CT. A live webcast and archived version of the presentation will be available on the company's investor relations website. CVRx focuses on neuromodulation solutions for cardiovascular diseases, with its Barostim™ therapy being FDA-approved for heart failure.
CVRx to Present at the William Blair 46th Annual Growth Stock Conference
CVRx, Inc. announced that its management team will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026, at 10:40 a.m. CT. A live webcast and archive of the presentation will be available on the company's investor relations website. CVRx is a medical device company specializing in neuromodulation solutions for cardiovascular diseases, featuring Barostim™, an FDA-approved technology for heart failure patients.
CVRx marks 25th Barostim implant milestone at UNC Medical Center Chapel Hill
CVRx announced the 25th successful Barostim implant at UNC Medical Center in Chapel Hill, highlighting the collaborative efforts of the medical team. This milestone follows a 20% increase in CVRx's first-quarter revenue and the commencement of patient enrollment for its BENEFIT-HF clinical trial, underscoring the company's growth and contributions to cardiac care.
CVRx Inc stock (US12674F1003): Medtronic takeover bid puts heart-device specialist in the spotlight
Medtronic has made an all-cash offer to acquire CVRx Inc for approximately $300 million, bringing the heart-device specialist into focus for investors. The acquisition highlights the strategic value of CVRx's Barostim device, which treats heart failure and hypertension, and Medtronic's aim to expand its cardiovascular portfolio. The deal provides CVRx with access to Medtronic's global infrastructure and offers liquidity to shareholders, reflecting how larger companies seek innovation from smaller, publicly traded firms.
Number of shareholders of CVRx, Inc. – NASDAQ:CVRX
This article provides details about CVRx, Inc. (NASDAQ: CVRX) within the TradingView platform. It navigates to the financial section of the company's profile. The content indicates that the market is closed and no trades are currently occurring.
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
CVRx, Inc. announced that Humana has issued a Medicare Advantage coverage policy for its Barostim therapy, effective May 1, 2026. This policy marks a significant milestone, expanding access for heart failure patients and validating CVRx's commercial strategy. Humana, a major national health insurance provider, will cover Barostim for patients meeting FDA-approved indications and those enrolled in the BENEFIT-HF trial.
The CVRx, Inc. (NASDAQ:CVRX) First-Quarter Results Are Out And Analysts Have Published New Forecasts
CVRx, Inc. shareholders experienced a 22% drop in share price after the company released its first-quarter results. Revenue of US$15m and a statutory loss of US$0.50 per share were in line with analyst forecasts. Analysts predict revenues of US$65.3m for 2026, with losses holding steady around US$1.95 per share, and the consensus price target remains unchanged at US$11.17, indicating that the business performance is meeting expectations despite the significant share price fall.
CVRx rebounds as Humana issues Medicare policy for Barostim
CVRx shares significantly increased after Humana, a major Medicare Advantage payer, issued a positive coverage policy for the company's Barostim therapy. This policy makes CVRx's Barostim available to Humana's 5.5 million Medicare Advantage members for heart failure treatment. The news is seen as a key step towards broader market adoption and increasing access for patients.
CVRx Inc | 10-Q: Q1 2026 Earnings Report
This document is the 10-Q filing for CVRx Inc, detailing its earnings report for the first quarter of 2026. This financial report provides a comprehensive overview of the company's performance, operations, and financial position during that period.
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
CVRx announced that Humana has issued a Medicare Advantage coverage policy for its Barostim therapy, effective May 1, 2026. This policy marks a significant milestone, expanding access to the heart failure treatment for Humana's 5.2 million Medicare Advantage members across 46 states. The coverage includes patients meeting FDA-approved indications and those in the BENEFIT-HF trial, following previous positive reimbursement developments this year.
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $14
Lake Street has reaffirmed its Buy rating on CVRx Inc (CVRX.US) and maintained its target price of $14. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
CVRx (CVRX) Q1 Loss Of US$13.1 Million Tests Bullish Revenue Growth Narrative
CVRx (CVRX) reported a Q1 2026 loss of US$13.1 million on US$14.8 million in revenue, with basic EPS at US$0.50. Despite ongoing losses and a forecast of unprofitability for at least three more years, analysts project annual revenue growth of 21.1% over the next three years. The stock currently trades at a 2.4x P/S, which is lower than the industry and peers, leading to a mixed outlook for investors balancing growth potential against persistent losses and insider selling.
Lake Street Initiates CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $14
Lake Street has initiated coverage on CVRx Inc (CVRX.US) with a "Buy" rating. The firm has set a price target of $14 for the company's stock. This indicates an optimistic outlook from Lake Street regarding CVRx's future performance.
CVRx, Inc. (NASDAQ:CVRX) Q1 2026 Earnings Call Transcript
CVRx, Inc. reported a strong start to 2026, exceeding revenue guidance with 20% total revenue growth and 22% U.S. growth, driven by investments made in the sales organization and reimbursement initiatives. The company addressed challenges with new Medicare Advantage prior authorization regulations, noting an initial increase in denials but expecting ultimate approval rates to remain strong. CVRx also highlighted the ongoing BENEFIT-HF trial, which aims to triple its addressable market and is positively impacting engagement with new centers.
CVRx, Inc. 1Q 2026: Revenue $14.77M, EPS ($0.5) — 10-Q Summary
CVRx, Inc. reported strong first-quarter 2026 results, with revenue increasing to $14.77M and diluted loss per share narrowing to ($0.5). The growth was driven by higher unit volume, increased average selling prices, and expansion in U.S. sales territories and active implanting centers. Gross margin also improved, and the company initiated a new randomized clinical trial.
CVRx (NASDAQ: CVRX) grows Q1 revenue 20% as net loss narrows
CVRx Inc. (NASDAQ: CVRX) announced Q1 2026 revenue of $14.8 million, a 20% increase year-over-year, primarily driven by U.S. heart failure sales. Despite continued investment in commercialization and R&D, the company's net loss narrowed to $13.1 million, and its gross margin improved to 87%. CVRx also expanded its loan facility and initiated a new at-the-market equity offering to support ongoing operations and growth strategies for its Barostim device.
Avoiding Lag: Real-Time Signals in (CVRX) Movement
This article provides a real-time analysis of Cvrx Inc. (NASDAQ: CVRX) stock movement, highlighting weak near-term and mid-term sentiment with a neutral long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, support, and resistance levels. The analysis suggests a current breakdown with expected lower levels and elevated downside risk.
CVRX: Q1 2026 delivered strong revenue growth, margin expansion, and strategic progress in U.S. heart failure therapy
CVRX achieved strong financial results in Q1 2026 with 20% revenue growth, improved gross margin, and a narrowed net loss, primarily driven by U.S. sales and successful reimbursement efforts. Key strategic advancements include the launch of the BENEFIT-HF trial and the transition to Category I CPT codes, which are expected to significantly expand market opportunities and support sustained long-term growth. This performance highlights the company's progress in its U.S. heart failure therapy initiatives.
CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates
CVRx (CVRX) reported a Q1 loss of $0.5 per share, slightly better than the Zacks Consensus Estimate of a $0.51 loss, and beat revenue estimates with $14.77 million. The company has surpassed revenue estimates three times in the last four quarters and has a Zacks Rank #2 (Buy), indicating potential for market outperformance. The medical device industry, to which CVRx belongs, ranks in the top 44% of Zacks industries.
Earnings call transcript: CVRx beats Q1 2026 forecasts, stock rises
CVRx, Inc. reported its Q1 2026 earnings, surpassing analyst expectations with an EPS of -$0.50 against a -$0.52 forecast and revenue of $14.8 million, exceeding the anticipated $14.4 million. The company's stock rose by 1.32% in after-hours trading following the announcement. Key drivers included robust U.S. market growth (22% year-over-year revenue increase) and an improved gross margin of 87%, while facing challenges in the European market and adapting to new Medicare Advantage prior authorization regulations.
Medical device company CVRx, Inc. has released its performance guidance for fiscal year 2026.
Medical device company CVRx, Inc. has issued its performance guidance for fiscal year 2026. The company expects annual revenue to be between $63 million and $67 million, with a gross margin of 85% to 87%. Operating expenses for the year are projected to be $103 million to $107 million, reflecting investments in R&D, sales, and marketing.
CVRx: Q1 Earnings Snapshot
CVRx Inc. (CVRX) reported a first-quarter loss of $13.1 million, or 50 cents per share, which exceeded Wall Street expectations. The medical device company also surpassed revenue forecasts, posting $14.8 million for the period. These results were generated by Automated Insights using data from Zacks Investment Research.
CVRx Reports First Quarter 2026 Financial and Operating Results
CVRx, Inc. announced its first-quarter 2026 financial results, reporting total revenue of $14.8 million, a 20% increase over the prior year, with U.S. revenue growing 22% to $13.7 million. The company initiated the BENEFIT-HF clinical trial and maintained its full-year 2026 revenue guidance between $63.0 million and $67.0 million, while updating its gross margin guidance to 85%-87%. CVRx, Inc. is a medical device company focused on neuromodulation solutions for cardiovascular diseases, with its Barostim™ technology approved by the FDA for heart failure.
CVRx (NASDAQ: CVRX) grows Q1 2026 revenue 20% but remains loss-making
CVRx Inc. reported a 20% increase in revenue for Q1 2026, reaching $14.8 million, largely driven by US sales. Despite narrowing its net loss to $13.1 million, the company remains unprofitable. CVRx provided Q2 2026 revenue guidance between $15.1 million and $16.1 million and maintained its full-year revenue and expense outlook.
CVRx Inc expected to post a loss of 50 cents a share - Earnings Preview
CVRx Inc. is expected to report an upcoming earnings loss of 50 cents per share. This information is provided as an earnings preview from Refinitiv.
CVRx (Nasdaq:CVRX) - Stock Analysis
CVRx Inc. (Nasdaq: CVRX) is a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases. The company's Barostim device recently began a large-scale BENEFIT-HF trial to expand its indicated patient population for heart failure. Despite analysts trimming price targets due to execution risks and profitability concerns, recent reports highlight strong clinical results and potential market growth, especially with new Category I CPT codes for Barostim therapy now in effect.
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating
Craig-Hallum has reiterated its Buy rating on CVRx Inc (CVRX.US). The article does not provide further details on the rationale behind this rating or any specific financial data.
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating
Craig-Hallum has reiterated its Buy rating for CVRx Inc (CVRX.US). The article title indicates the firm's continued positive outlook on the company.
Earnings Preview: CVRx Inc to Report Financial Results Post-market on May 11
CVRx Inc (CVRX) is scheduled to release its financial results after market close on May 11. Analysts are forecasting a loss of $0.30 per share and revenue of $16.59 million for the upcoming report. Investors will be observing the company's performance and future outlook as indicated in its earnings release.
First patient enrolled in massive heart failure trial
CVRx has begun enrolling patients for its BENEFIT-HF trial, a large-scale study of the implantable Barostim device for heart failure treatment, aiming for 2,500 participants across the U.S. and Germany. The study targets heart failure patients with specific functional class and ejection fraction criteria who remain symptomatic despite guideline-directed medical therapy. This trial could significantly expand the indicated patient population for Barostim, a device that uses electrical pulses to regulate heart function.
CVRx enrolls first patient in 2,500-patient heart failure trial
CVRx Inc. has enrolled the first patient in its large-scale BENEFIT-HF clinical trial, which aims to evaluate its Barostim device for heart failure patients across 150 centers in the U.S. and Germany. The company, which reported strong preliminary Q1 results and maintains an 85% gross profit margin, views this trial as a crucial step to potentially triple the indicated patient population for Barostim. Analysts have maintained positive ratings, with one firm reiterating an Outperform and another a Buy rating despite a lowered price target.
CVRx enrolls first patient in study of Barostim therapy for heart failure
CVRx has enrolled the first patient in its landmark BENEFIT-HF study for its Barostim therapy, which delivers electrical pulses to activate baroreceptors and reduce heart failure symptoms. The study aims to evaluate Barostim in a broader heart failure patient population, enrolling 2,500 patients across 150 centers in the U.S. and Germany, with results expected by 2032. This milestone marks significant excitement within the healthcare community for the trial and its potential to define Barostim's role in the treatment of heart failure.
CVRx launches landmark BENEFIT-HF trial for cardiac device research
CVRx has initiated the BENEFIT-HF trial, a significant study for cardiac devices, with the first patient enrolled at North Central Heart in Sioux Falls, South Dakota. Led by Dr. Orvar Jonsson, the trial aims to evaluate innovative approaches in heart failure treatment. This follows CVRx's previous work introducing its Barostim device, which has shown to improve the quality of life for heart failure patients.
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx, Inc. has announced the enrollment of the first patient in its landmark BENEFIT-HF trial, which aims to evaluate Barostim therapy in a significantly expanded heart failure population. This large-scale trial will enroll 2,500 patients across 150 centers in the U.S. and Germany and is designed to assess all-cause mortality and heart failure decompensation events. If successful, the trial, expected to conclude in 2032, could triple the indicated patient population for Barostim, greatly increasing access to the therapy.
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx, Inc. announced the enrollment of the first patient in its landmark BENEFIT-HF trial, which aims to evaluate the Barostim therapy in a broader population of heart failure patients. This large-scale, randomized, controlled study, involving 2,500 patients across 150 centers in the U.S. and Germany, is supported by CMS Category B IDE coverage and seeks to significantly expand the indicated patient population for Barostim if successful. The trial is expected to continue through 2032, generating crucial data to further define Barostim’s role in heart failure treatment.
A 2,500-patient heart failure study begins with device access at stake
CVRx (NASDAQ: CVRX) has announced the enrollment of the first patient in its landmark BENEFIT-HF trial, a large-scale study evaluating its Barostim device for heart failure. This prospective, randomized trial aims to enroll 2,500 patients across 150 centers in the U.S. and Germany, with results expected by 2032. A successful outcome could significantly expand access to the Barostim therapy by tripling its indicated patient population.
CVRx enrolls first patient in BENEFIT-HF trial to expand Barostim heart failure therapy use
CVRx, Inc. has announced the enrollment of the first patient in its BENEFIT-HF trial, a significant study designed to evaluate the Barostim therapy in a broader population of heart failure patients. This trial aims to enroll 2,500 patients across 150 centers in the US and Germany to assess mortality and heart failure events. A successful outcome could potentially triple the number of eligible patients for Barostim, an FDA-approved neuromodulation device, thus expanding its use in heart failure treatment.
CVRx reports Barostim therapy boosts quality of life for heart failure patients
CVRx announced that its Barostim therapy significantly improves the quality of life for heart failure patients, a finding highlighted by Dr. Savitri Fedson. The company had previously forecast first-quarter 2026 revenue of $14.7 million to $14.8 million, representing a 20 percent increase from the prior year. CVRx continues to focus on Barostim’s therapeutic potential and commercial growth, reinforced by sessions at ISHLT2026 focusing on neurohormonal targeting and heart failure treatment innovations.
Discipline and Rules-Based Execution in CVRX Response
Stock Traders Daily's AI models provide analysis for Cvrx Inc. (NASDAQ: CVRX), identifying a weak near-term sentiment but long-term strength. The report details various trading strategies, including long, momentum breakout, and short options, along with multi-timeframe signal analysis to manage risk and optimize positions for different investment horizons.
Methodist University Hospital completes first Barostim implant with CVRx collaboration
Methodist University Hospital successfully completed its first Barostim implant, a heart failure treatment device from CVRx, in collaboration with Dr. Jonathan Nitz and Dr. Yehoshua Levine. This marks a new advanced treatment option for patients unresponsive to conventional therapies. CVRx projects significant revenue growth for Q1 2026 and continues to expand Barostim's clinical presence.
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
CVRx (NASDAQ: CVRX) announced it will release its first-quarter 2026 financial results after market close on Monday, May 11, 2026. The company will also host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss the results. Investors can access the webcast via CVRx's investor relations website or dial in by phone.
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
CVRx, Inc. announced it will release its first quarter 2026 financial and operating results after market close on Monday, May 11, 2026. The company will also host a conference call at 4:30 p.m. ET on the same day to discuss the results. Interested parties can access the webcast on the company's investor relations page or join via telephone.
CVRx, Inc. (NASDAQ:CVRX) Receives Average Rating of "Moderate Buy" from Analysts
CVRx, Inc. (NASDAQ:CVRX) has received an average "Moderate Buy" rating from analysts, with a 1-year average price target of $10.50, despite missing recent Q4 earnings estimates. The company reported ($0.46) EPS against an estimated ($0.42) and $16.02 million in revenue. Insider activity shows Director Mudit K. Jain increased his stake by purchasing 46,800 shares.
CVRx promotes Barostim therapy as new option for heart failure patients at ISHLT2026
CVRx is highlighting its Barostim device at ISHLT2026, positioning it as a new treatment option for heart failure patients to enhance exercise capacity and quality of life. The company advocates for Barostim's use in conjunction with guideline-directed medical therapy (GDMT) to improve patient outcomes by targeting the neurohormonal pathway. CVRx previously presented data at ACC26 and reported an estimated 20% increase in preliminary Q1 2026 revenue.
CVRx reports preliminary 2025 results, issues 2026 guidance
CVRx has reported its preliminary financial results for 2025 and provided guidance for 2026. This announcement gives investors and analysts an early look at the company's performance and future expectations. The specific financial figures and guidance details are crucial for understanding the company's trajectory.
Lawnwood Medical Center achieves milestone with 15th Barostim therapy, CVRx confirms
Lawnwood Medical Center, in collaboration with Dr. Philip Seibel, has successfully completed its 15th Barostim implant, a therapy by CVRx. This milestone underscores their commitment to offering innovative solutions for heart failure patients. CVRx previously highlighted Barostim's potential to improve exercise capacity and forecasted Q1 2026 revenue between $14.7 million and $14.8 million, indicating significant growth.
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
CVRx, Inc. announced the nomination of Michael Dale to its Board of Directors, with a vote scheduled for the annual meeting on June 1, 2026. Dale brings extensive executive and board experience from various medical device companies, most recently as CEO of Axogen, Inc. His expertise is expected to be invaluable as CVRx continues to expand the adoption of its Barostim therapy for heart failure.
CVRx (CVRX) details 2026 virtual meeting, board nominees and pay
CVRx, Inc. will hold its 2026 annual shareholder meeting virtually on June 1, 2026, where stockholders will vote on the election of three Class II directors, including CEO Kevin Hykes and new nominee Michael Dale, and the ratification of Grant Thornton as the independent auditor. The company is set to lose its "emerging growth company" status by December 31, 2026, which will lead to increased reporting requirements. The proxy statement also details executive and director compensation, with CEO Kevin Hykes' total compensation for 2025 reported as over $3.9 million, and outlines the significant ownership stakes of major stockholders like Johnson & Johnson.
Former Abbott structural heart leader Michael Dale lands CVRx board nomination
CVRx, Inc. (NASDAQ: CVRX) announced the nomination of Michael Dale to its Board of Directors, with the election scheduled for June 1, 2026. Dale, currently CEO of Axogen and former head of Abbott's structural heart division for eight years, is expected to bring extensive commercial and leadership experience to drive Barostim adoption. His nomination is seen as a strategic move to leverage his expertise in the medical device industry for the company's growth.
